Compare · ABBV vs ZTS
ABBV vs ZTS
Side-by-side comparison of AbbVie Inc. (ABBV) and Zoetis Inc. (ZTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ZTS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $469.68B, about 14.7x ZTS ($31.94B).
- ABBV has been more active in the news (17 items in the past 4 weeks vs 9 for ZTS).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Zoetis Inc.
- Price
- $262.41-1.25%
- $78.47+1.52%
- Market cap
- $469.68B
- $31.94B
- 1M return
- -0.24%
- -
- 1Y return
- +26.00%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- 2013
- News (4w)
- 17
- 9
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Latest ABBV
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest ZTS
- New insider Saccaro James claimed no ownership of stock in the company (SEC Form 3)
- Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
- Director Damelio Frank A gifted 6,650 shares, decreasing direct ownership by 31% to 14,808 units (SEC Form 4)
- SEC Form 8-K filed by Zoetis Inc.
- SEC Form 10-Q filed by Zoetis Inc.
- Zoetis downgraded by William Blair
- Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zoetis Announces Second Quarter 2026 Results
- Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
- Zoetis Launches Portela® (relfovetmab) in Canada and the European Union